CURE Pharmaceutical Holding Corp. (OTCQB: CURR) revenue in the third quarter increased 32.1% year-over-year and 58.9% sequentially from Q2 2022 to $1.8 million.
Q3 2022 Financial Highlights
Gross profit was $1.4 million compared to $914,000 in Q3 2021.
Gross margins for the third quarter improved by 123 basis points to 80.0% in 2022 compared to the same period in 2021.
Net loss was $3.6 million compared to $4.3 million in Q3 2021.
CURE completed the sale of a portion of its platform technology intellectual property portfolio and related assets in July 2022 for $20 million …